相关实验视频

Updated: Jan 7, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

瘤肌瘤透T细胞预测了NSCLC中抗CTLA-4抗体的有效性

Hiroshi Saijo^1,2, Yoshihiko Hirohashi², Toshiyuki Sumi³

¹Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, Japan; h_saijo@h-keiaikai.or.jp.

Anticancer research

|December 30, 2025

概括

在非小细胞肺癌 (NSCLC) 患者中,CD8+和FOXP3+ T细胞的高 stromal 透率可能预测抗CTLA-4抗体治疗对非小细胞肺癌 (NSCLC) 患者具有低PD-L1表达的益处,尽管存在与免疫相关的不良事件的风险.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
癌症研究癌症研究

背景情况:

在晚期/复发性NSCLC中使用抗PD-1/PD-L1和抗CTLA-4抗体的组合疗法的最佳选择标准尚不清楚.
虽然抗CTLA-4疗法在PD-L1<1%的NSCLC中显示出潜在的潜力,但免疫相关不良事件 (irAEs) 的增加是令人担忧的.
生物标志物是指导在NSCLC中使用抗CTLA-4抗体的必要条件.

研究的目的:

调查瘤透淋巴细胞 (CD8+,FOXP3+) 的瘤内 (iTIL) 和瘤内 (sTIL) 淋巴细胞 (CD8+,FOXP3+) 作为在NSCLC中抗CTLA-4治疗疗效的生物标志物的作用.
评估TIL透与NSCLC患者的临床结果之间的关联,PD-L1<1%的患者接受了尼沃卢马布加上伊皮利穆马布治疗.

主要方法:

在NSCLC标本中检测CD8+和FOXP3+iTILs和stils的免疫组织化学染色.
单变异性,多变异性和卡普兰-梅尔分析,以评估TIL和临床疗效 (无进展生存率,总生存率) 之间的相关性.
在PD-L1<1%的NSCLC患者接受nivolumab加上ipilimumab的评估.

主要成果:

高的sTIL透与无进展生存率有显著的相关性.
受访者显示CD8+较高,FOXP3+ iTILs较低,CD8+和FOXP3+ sTILs较高.
高CD8+ sTIL显著预测了延长整体存活;高FOXP3+ sTIL显示了改善整体存活的趋势.

结论:

患有CD8+和FOXP3+T细胞高层透的患者可能从抗CTLA-4抗体治疗中受益.
评估这些结构性免疫参数可以帮助患者选择抗CTLA-4疗法.
这种方法可能有助于优化NSCLC的治疗结果,尽管存在irAE风险.

关键词:

在NSCLCLC中,我们可以看到NSCLCLC.这就是Treg Treg.在瘤中,瘤流体 (stroma) 形成.对抗CTLA-4抗体的抗体生物标志物生物标志物

更多相关视频

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...